Beodeul Kang

7PUBLICATIONS
76CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersMolecular targetsPalliative care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 02, 2026
Prognostic Value of FDG PET/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel.

Jeong Won Lee, Sang Mi Lee, Beodeul Kang

|Nov 13, 2025
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon

|Apr 21, 2025
Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy.

Jeong Won Lee, Sang Mi Lee, Beodeul Kang

|Jan 17, 2025
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).

In-Ho Kim, Seung Joo Kang, Wonyoung Choi

|Nov 07, 2024
Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy.

Seung Yeon Lee, Min Je Sung, Suk Pyo Shin

|Feb 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.

Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim

Pageof 2

Frequent Collaborators

3 joint publications

Jeong Won Lee

3 joint publications

Hong Jae Chon

2 joint publications

Hyung-Don Kim

2 joint publications

Su Jin Jang